The leukaemia drug will bridge a long-pending unmet need in cancer therapy
Ahmedabad-based Intas Pharmaceuticals has launched oral azacitidine in India under the brand name Azadine-O. Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It is the first drug that will improve survival by almost ten months and bridge a long-pending unmet need in cancer therapy.
In 2014, Intas triggered a paradigm change in the treatment of MDS – myelodysplastic syndrome with the launch of AZADINE (Injectable Azacitidine). Azadine-O is yet another progressive breakthrough in the treatment of Acute Myeloid Leukemia.
Prof (Dr) MB Agarwal, said, “Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients.”